last updated: 2 months ago

last updated: 2 months ago

Intelligencia AI logo

Intelligencia AI

Intelligencia AI

Intelligencia AI

Applying machine learning in drug development

Applying machine learning in drug development

Software Development

Software Development

New York

New York

US

US

51–200 employees

51–200 employees

January 2017

January 2017

Overview

Overview

Intelligencia AI uses artificial intelligence to de-risk drug development. Our platform focuses on estimating the risk of clinical trials, and interpreting the multitude of factors that contribute to that risk. We bridge the gap between innovation and risk reduction, with the ultimate goal of bringing novel therapies to patients faster.

Our interdisciplinary team of software engineers, AI practitioners, scientists, and drug developers combines and interprets disparate data across the life sciences industry. Our platform offers a suite of functionalities that provide unprecedented data clarity and Machine-Learning predictions to enable critical decision-making.

We currently work with several of the largest global pharmaceutical companies as well as mid-size and smaller biotechnology companies.

Diseases will impact nearly every individual. At Intelligencia AI, we work to make a difference.

Intelligencia AI uses artificial intelligence to de-risk drug development. Our platform focuses on estimating the risk of clinical trials, and interpreting the multitude of factors that contribute to that risk. We bridge the gap between innovation and risk reduction, with the ultimate goal of bringing novel therapies to patients faster.

Our interdisciplinary team of software engineers, AI practitioners, scientists, and drug developers combines and interprets disparate data across the life sciences industry. Our platform offers a suite of functionalities that provide unprecedented data clarity and Machine-Learning predictions to enable critical decision-making.

We currently work with several of the largest global pharmaceutical companies as well as mid-size and smaller biotechnology companies.

Diseases will impact nearly every individual. At Intelligencia AI, we work to make a difference.

Key personnel profiles

Key personnel profiles

Key personnelS

Dimitrios Skaltsas

Co-Founder & CEO, Intelligencia AI: De-risking drug development| Inc. 5000 x2| Executive in Residence, AI at INSEAD

view profile

Gerry Liaropoulos

Chief AI Officer at intelligencia.AI

view profile

Hiring Trend

Hiring Trend

TOTAL hires

TOTAL hires

7

7

MAR'26APR'26MAY'26JUN'26
MAR'26APR'26MAY'26JUN'26

Employee Growth

Employee Growth

TOTAL EMPLOYEES

TOTAL EMPLOYEES

110

110

6m GROWTH

6m GROWTH

-4%

-4%

1y GROWTH

1y GROWTH

-4%

-4%

OCT'25NOV'25DEC'25JAN'26FEB'26MAR'26APR'26MAY'26JUN'26JUL'26AUG'26SEP'26
OCT'25NOV'25DEC'25JAN'26FEB'26MAR'26APR'26MAY'26JUN'26JUL'26AUG'26SEP'26

Employee Distribution & Department Growth

Employee Distribution & Department Growth

TOTAL EMPLOYEES

TOTAL EMPLOYEES

110

110

6m GROWTH

6m GROWTH

1y GROWTH

1y GROWTH

Department distribution

Department distribution

Department distribution

DEPARTMENT

6m GROWTH

1y GROWTH

Research

Research

Research

0%

0%

0%

-11%

-11%

-11%

Engineering

Engineering

Engineering

-17%

-17%

-17%

-12%

-12%

-12%

Information Technology

Information Technology

Information Technology

0%

0%

0%

25%

25%

25%

Business Development

Business Development

Business Development

-9%

-9%

-9%

-9%

-9%

-9%

Product Management

Product Management

Product Management

0%

0%

0%

0%

0%

0%

Web Engagement

pages per visit

pages per visit

1.7

1.7

monthly visits

monthly visits

4,213

4,213

JUN'26JUL'26AUG'26
JUN'26JUL'26AUG'26

Web Traffic by Country

Web Traffic by Country

United States

66.1%

United States

66.1%

India

33.9%

India

33.9%

Web Traffic Sources

Web Traffic Sources

monthly visits

4,213

Direct

27.1%

Direct

27.1%

Search

37.5%

Search

37.5%

Social

7.8%

Social

7.8%

Referrals

7.5%

Referrals

7.5%

AI

2.3%

AI

2.3%

funding round

funding round

1

total funding raised

total funding raised

$12M

last round type

last round type

Series A

last round amount

last round amount

$12M

announced on

announced on

$12M

funding round

1

total funding raised

$12M

last round type

Series A

last round amount

$12M

announced on

$12M

lead investors

lead investors

lead investors

MTIP, Big Pi Ventures, Synetro Group, ZS, Bantam Group, ByTheTower

MTIP, Big Pi Ventures, Synetro Group, ZS, Bantam Group, ByTheTower

Recent News & Articles

Recent News & Articles

A network graph of your entire TAM. We find the path into every account worth a meeting, and book it.

Powered by NVIDIA and AWS.

RESOURCES

Made with love.

© 2026 InGrow. All rights reserved.

A network graph of your entire TAM. We find the path into every account worth a meeting, and book it.

Powered by NVIDIA and AWS.

RESOURCES

Made with love.

© 2026 InGrow. All rights reserved.

A network graph of your entire TAM. We find the path into every account worth a meeting, and book it.

Powered by NVIDIA and AWS.

RESOURCES

Made with love.

© 2026 InGrow. All rights reserved.

A network graph of your entire TAM. We find the path into every account worth a meeting, and book it.

Powered by NVIDIA and AWS.

RESOURCES

Made with love.

© 2026 InGrow. All rights reserved.